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Abstract
In genetically heterogeneous mice produced by the CByB6F1 x C3D2F1 cross, the
“non-feminizing” estrogen, 17-α-estradiol (17aE2), extended median male lifespan by
19% (p < 0.0001, log-rank test) and 11% (p = 0.007) when fed at 14.4 ppm starting at 16 and 20 months, respectively. 90th percentile lifespans were extended 7%
(p = 0.004, Wang–Allison test) and 5% (p = 0.17). Body weights were reduced about
20% after starting the 17aE2 diets. Four other interventions were tested in males
and females: nicotinamide riboside, candesartan cilexetil, geranylgeranylacetone, and
MIF098. Despite some data suggesting that nicotinamide riboside would be effective,
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neither it nor the other three increased lifespans significantly at the doses tested. The
17aE2 results confirm and extend our original reports, with very similar results when
started at 16 months compared with mice started at 10 months of age in a prior study.
The consistently large lifespan benefit in males, even when treatment is started late in
life, may provide information on sex-specific aspects of aging.
KEYWORDS

17-α-estradiol, candesartan cilexetil, geranylgeranylacetone, heterogeneous mice, lifespan,
macrophage migration inhibitory factor, nicotinamide riboside
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range of species. Importantly, increasing NAD levels benefit a wide
variety of tissues in species including mice and human beings.

Each year, the Interventions Testing Program (ITP; http://www.nia.

Rajman et al. (2018), for example, suggest that NAD+boosters may

nih.gov/research/dab/interventions-testing-program-itp) tests the

“..delay aging and age-related physical decline.” Zhang et al. (2016)

effects of a variety of compounds on lifespan in a genetically hetero-

reported that NR delays senescence of neural SCs and melanocyte

geneous mouse model (UM-HET3), the first-generation offspring of

SCs and increases mouse life span, even when given in old age (5%

the CByB6F1 x C3D2F1 cross, to produce a diverse heterogeneous

increase at 20 months of age).

population that is reproducible across time and place (Roderick,

Trammell, Schmidt, et al. (2016) reported that in mice and hu-

1963). ITP studies are conducted simultaneously at The University

mans NR is bioactive when given by mouth, unlike most other nico-

of Texas (UT), University of Michigan (UM), and The Jackson

tinamide derivatives. In 2016b, they reported that NR improved liver

Laboratory (TJL) in Bar Harbor, ME. Details of the ITP design have

function and protected against diabetic neuropathy. When fed to

been published (Harrison et al., 2009; Harrison et al., 2014; Harrison

C57BL/6 J mice from 10 weeks of age, NR protects against high-

et al., 2019; Macchiarini et al., 2020; Miller et al., 2011, 2014; Miller,

fat diet (HFD)-induced obesity and promotes oxidative metabolism

Harrison, et al., 2020; Strong et al., 2008, 2016, 2020). Interventions

by increasing the NAD+/NADH ratio in muscle, liver, and brown

that are found, in an initial experiment, to increase lifespan are then

adipose tissue (Canto´et al., 2012). Ryu et al. (2016) found that in-

subsequently tested for physiological and pathological changes with

creasing NAD+stores with NR supplementation improved muscle

age. The data in this paper come from the initial survival cohorts, and

function and alleviated heart defects in a mouse model of muscu-

thus focus on lifespans, which integrate all biological effects that

lar dystrophy. Mitchell et al. (2018) reported that an NR metabolite,

may lead to death. The spectrum of lethal pathology in UM-HET3

nicotinamide, did not increase lifespan when started at 12 months

mice has been tabulated by Lipman et al. (2004), using groups of 136

in C57BL/6 J mice but improved some health outcome measures.

and 208 virgin females, 268 multiparous females, plus 117 and 157

Due to its benefits in a variety of diseases, and reports of benefits

virgin males.

in mouse lifespans, NR treatment was proposed to increase lifespan

The interventions for the present study were chosen for the following reasons:

in UM-HET3 mice.
c) Candesartan cilexetil (CC) is an angiotensin-receptor blocker,

(a) 17-α-estradiol (17aE2) is a relatively “non-feminizing” estro-

which lowers blood pressure (Ikeda et al., 2006) and improves car-

gen which shows reduced activation of classical estrogen recep-

diovascular function and insulin sensitivity in obese, hypertensive

tors compared with 17-β-estradiol (Anstead et al., 1997). Harrison

patients (Grassi et al., 2003). Importantly, angiotensin-receptor

et al. (2014) reported that in UM-HET3 mice fed 4.8 mg 17aE2/

knockout increases lifespan of mice (Benigni et al. 2009). Because

kg (4.8 ppm) diet from 10 months of age, median male lifespans in-

CC is effective against age-related diseases, and sensitizes the body

creased 12% (p = 0.0012, pooled across the three sites), while 17aE2

to insulin, and because the angiotensin-receptor knockout increases

did not alter female lifespan. Strong et al. (2016) showed that using

lifespan of mice, treatment with CC was hypothesized to increase

a threefold higher dose (14.4 ppm) from 10 months of age, pooled

lifespan.

median male lifespans increased 19% (p < 0.001); the 90% lifespan

(d) To maintain good quality protein in the body, heat shock pro-

increased 12%, but females still did not benefit. Thus, only males

teins (HSPs) are vital. Geranylgeranylacetone (GGA) induces heat

were tested in the present study. To determine whether 17aE2 treat-

shock protein (Hsp70) in mammalian tissues and promotes insulin

ment is effective when initiated in older mice, males were treated

sensitivity in old mice (Silverstein et al., 2015), while van Marion

beginning at 16 or 20 months of age, choosing middle age, and early

et al. (2020) showed that it increases HSP expression in atrial tis-

old age before many natural deaths.
(b) Nicotinamide riboside (NR) is a precursor of nicotinamide ad-

sue after heart surgery. Pride et al. (2015) showed that long-lived
species, compared with related short-lived species within the same

enine dinucleotide (NAD) via the cell's salvage pathway (Trammell,

order, have elevated HSP levels in conjunction with better proteo-

Schmidt, et al. (2016)). Total NAD levels decline with age, in a wide

stasis. To test whether treatment with an established HSP inducer

|
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can increase lifespan in a mammalian model, UM-HET3 mice were

Interventions that are effective when started at a late age have consid-

treated with GGA.

erable translational potential.

(e) MIF098 ((3-(3-hydroxybenzyl)-5 -m ethylbenzo[d]oxazol-
2(3H)-o ne) is a macrophage migration inhibition factor (MIF) antagonist that regulates CD44 binding (Yoo et al., 2016). MIF is

2
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a proinflammatory cytokine, so MIF098 reduces inflammation.
This may include the chronic inflammation that increases with

Compared to controls, UM-HET3 male mice fed a diet with 14.4 ppm

age, as suggested by the finding of Harper et al. (2010) that MIF-

17aE2 starting at 16 or 20 months of age had, respectively, 19%

knockout mice live significantly longer than controls. Because it

(p < 0.0001, log-rank test) and 11% (p = 0.007) increases in median

is orally bioavailable and shows MIF inhibitory activity in mouse

lifespans (data pooled across three sites). Lifespans at the 90th per-

models of hyperoxic lung injury, as well as in other diseases

centile were significantly increased 7% when treatment was started

(Sauler et al., 2015), treatment with MIF098 was proposed to in-

at 16 months (p = 0.004, Wang–Allison statistic); however, when

crease lifespan by decreasing chronic inflammation and disease

treatment was started at 20 months, the 5% increase in the 90th

(Poulsen et al., 2019).

percentile lifespan was not significant (p = 0.17) (Table 1; Figure 1).

Our new data show that Nicotinamide riboside (NR) failed to in-

These data hint that benefits from 17aE2 diminish when treatment

crease lifespan. Only 17aE2 increased lifespan, and benefits in males

is started at 20 rather than at 16 months; however, when comparing

occurred even when the drug was not fed until late middle or early

the median lifespan results between the two treatment groups, no

old age (16 and 20 months of age, respectively). The range of ages

significant difference was detected (p = 0.24, log-rank test).

for which treatment is effective suggests that benefits from 17aE2

Mice were weighed every 6 months beginning at 6 months of

do not depend on effects earlier in life, such as growth alteration.

age. Prior to treatment, at 6 and 12 months of age, the mean weight

TA B L E 1 Effects of interventions on
lifespan; data pooled from the 3 sites

Median lifespan
Group

%
change

Lifespan at 90th percentile
Log-rank
p-value

%
change

Wang–Allison
p-value

1068

2%

0.99

1120

7%

0.092

0.72

1081

3%

0.176

0.069

1028

–2%

0.314

1120

7%

0.004

1103

5%

0.174

0.252

1019

−3%

0.99

0.370

1055

1%

0.733

5%

0.720

1070

2%

0.730

4%

0.645

1055

1%

0.99

N

Days

Cont_16

304

874

NR

136

875

0%

0.612

CC

136

880

1%

0.235

GGA

136

894

2%

MIF098

136

863

−1%

Cont_16

303

787

17aE2 16

156

933

19%

<0.0001

17aE2 20

159

871

11%

0.007

NR

156

763

−3%

CC

156

820

4%

GGA

156

825

MIF098

156

821

Days

Females
1047

Males
1047

Lifespans of ITP mice from cohort 2016.
Group: Cont_16 fed control diet; 17aE2 16 and 20 fed 14.4 ppm 17-α-estradiol starting at 16 and
20 months of age. Mice started on diets at 8 months of age were those fed: NR with 1,000 ppm
nicotinamide riboside, CC with 30 ppm candesartan cilexetil, and MIF098 with 240 ppm MIF098.
GGA mice were fed 600 ppm geranylgeranylacetone starting at 9 months of age.
N = number of mice tested; data were pooled, with about 1/3 of the mice from each testing site;
see Table 2 caption for details.
Under Median lifespan: Days—median ages; % change calculated with respect to controls.
p-value = probability that lifespans are the same as the controls using two-t ailed log-rank test
on pooled data stratified by sites; "removed" mice were included as censored (see Experimental
Procedures).
Under lifespan at 90th percentile: Days = age at 90th percentile, % change from control.
Wang–Allison p-value = probability that the proportion of live mice is the same in treated as in the
control group at the 90th percentile age, evaluated by the procedure of Wang et al. (2004).
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of each group of mice designated for treatment was comparable to

Site-specific effects on lifespans were also not significant, although the

the weight of the group designated as the untreated control group.

site-specific data sets had far less statistical power (Table 2). NR led to

Weights of male mice started on 17aE2 at 16 months decreased

a marginally significant increase in female lifespan at one site, but this

about 20% by 18 months, and weights of mice started on 17aE2

was balanced by a marginally significant decline in female lifespan at

at 20 months decreased about 20% by 24 months (Figure 2B). At

another (as well as a marginally significant decline in lifespans of males

24 months, the weights of both of the 17aE2 treatment groups were

at a single site) (Table 2). The ITP primary endpoint is always the pooled

similar, and both were about 8.5 g lighter than controls (p < 0.001 in

data set, and NR had no significant effect, positive or negative, in the

both cases).

pooled data sets for either sex. Figure 2 gives effects of these agents

Comparing median lifespans across individual sites (Table 2),

on body weights. In females, weights of mice fed GGA were similar to

starting males on 17aE2 diets at 16 months increased lifespans 20%

weights in controls, while females fed NR, CC, and MIF098 were about

at both TJL (p = 0.001, log-rank test) and UT (p < 0.0001), with a

5 g lighter than controls. In males, weights of mice fed NR, CC, GG, and

16% increase at UM (p = 0.06). Starting 17aE2 diets at 20 months

MIF098 were similar to weights in controls.

increased lifespans 17% at TJL, 11% at UM, and 5% at UT; only the

As detailed in the Experimental Procedures, NR, CC, GGA, and

17% increase was significant (p = 0.02). Comparing median lifespans

MIF098 were each present in the diet pellets at about the amounts

within each site, starting 17aE2 treatment at 16 months tended

expected. Nicotinamide was detected in serum at the following lev-

to increase lifespans more than starting treatment at 20 months

els (mean ± SD [n], ng/ml): controls 105 ± 46 (n = 19) and NR-treated

(Table 2), although the difference reached significance only at UT

401 ± 212 (n = 31), with males and females pooled because their re-

(p = 0.003).

sults were similar. Treated mice had significantly more nicotinamide

Lifespans for pooled data (across the three sites) were not signifi-

(p < 0.0001 by Mann–Whitney test). No NR was detected, but the

cantly affected in UM-HET3 males or females fed diets with 1,000 ppm

detection limit was 500 ng/ml, while that of nicotinamide was 25 ng/

nicotinamide riboside (NR), 30 ppm candesartan cilexetil (CC), 600 ppm

ml. Possibly, by the time NR was in the blood, it had already been

geranylgeranylacetone (GGA), or 240 ppm MIF098 (Table 1, Figure 3).

metabolized to nicotinamide.
In a separate study, NR and its metabolites were tested in liver,
brain cortex, plasma, gastrocnemius muscle, heart, kidney, iWAT (inguinal white adipose tissue), gWAT (perigonadal white adipose tissue), and leg muscle from 6-  to 10-month-old UM-HET3 mice fed
control or 1,000 ppm NR diet for 6–6.5 weeks, with 3 males and 4
females per group. The most interesting positive finding was lower
levels (p = 0.004) of nicotinamide in cortex (though not liver) of NR-
treated mice. NR-treated mice also had lower NR levels in cortex
(but not in liver), compared with controls (p = 0.03). The ratio of NAD
to NADH in the cortex was lower in NR-treated males (p = 0.012).
These results are preliminary, because numbers of mice tested were
low, and the diets were only fed to young mice for 6 weeks.
Candesartan (but not CC) was found in plasma of all four female
and three male UM-HET3 mice fed CC for 8 weeks: values (ng/ml)
for the females were 25, 44, 19, and 49; values for the males were
40, 26, and 23. The four female and three male controls all had less

F I G U R E 1 Effects of 17aE2 on lifespan curves showing male
control and males fed 17aE2 diets started at 16 months or at
20 months of age. Table 1 gives more details on these lifespans

than the 5 ng/ml detection limit of CC. In mice receiving dietary GGA
and MIF098, amounts were below detection limits in serum (1 µg/ml
and 15 ng/ml, respectively).

F I G U R E 2 Effects of interventions on
body weights. Panel A shows females,
and Panel B shows males. Weights are
from the same mice whose lifespans are
shown in Table 1. Control mice were fed
the control diet; 17aE2 started at 16 or
20 months of age. CC, MIF098, and NR
were fed from 8 months of age, while
GGA was fed from 9 months of age

|
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TA B L E 2 Effects of Est-16 and NR on median lifespan at each ITP site
TJL
Group

Days

UM
% change

p-value

Days

UT
% change

p-value

Days

% change

p-value

Mean %
change

Females
Cont_16

883

858

882

NR

968

10%

0.040

799

−7%

0.033

857

−3%

0.335

0%

CC

896

1%

0.124

867

1%

0.371

876

−1%

0.413

0%

GGA

905

2%

0.461

916

7%

0.152

892

1%

0.930

3%

MIF098

895

1%

0.874

836

−3%

0.084

866

−2%

0.347

−1%

Males
Cont_16

752

826

799

17aE2 16

906

20%

0.006

943

14%

0.110

955

20%

0.0001

18%

17aE2 20

896

19%

0.027

900

9%

0.160

840

5%

0.444

11%

NR

757

1%

0.968

852

3%

0.398

712

−11%

0.019

−3%

CC

826

10%

0.035

866

5%

0.487

770

−4%

0.689

4%

GGA

787

5%

0.729

914

11%

0.156

801

0

0.875

5%

MIF098

829

10%

0.228

810

−2%

0.721

826

3

0.491

4%

For each site, TJL (the Jackson Laboratory), UM (University of Michigan), UT (University of Texas), numbers in treated groups were 51–54 per site for
males and 44–48 for females; numbers of controls were 99–102 for males and 92–116 for females.
This table lists: Group—the same as Table 1. Days = median survival in days, % change from control, and the log-rank P that the group differs from the
controls (Cont_16). The rightmost column shows the average (mean) of the changes in median lifespan across the three sites.

F I G U R E 3 Lifespan curves of controls,
and the 4 interventions without effects/.
Panel A shows females, and Panel B
shows males. Data are from the same mice
whose lifespans are shown in Table 1

3
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DISCUSSION

comparable. In an earlier study from the ITP, Strong et al. (2016) found
a 19% increase in lifespan when mice were given 14.4 ppm 17aE2 from

Earlier ITP studies found that 17aE2 treatment, initiated at

10 months of age (17aE2-fed, 925 days; controls, 780 days). In the

10 months of age, increased lifespan in UM-HET3 males but had no

current study, median lifespans were similar, despite being collected

effect on UM-HET3 females. To determine whether later onset of

5 years later and starting the 17aE2 diet at 16 rather than 10 months

17aE2 treatment is comparably effective, we evaluated UM-HET3

of age (17aE2-fed, 933 days; controls, 787 days) (Table 1). Results for

males treated with 17aE2 initiated at either 16 or 20 months of age,

lifespan at the 90th percentile differed slightly. Strong et al. (2016)

roughly equivalent to humans of 50 and 60 years of age. Lifespan

found a 12% increase when treatment was started at 10 months; in

was significantly increased in both treatment groups compared with

the current study, the 90th percentile lifespan increased 7% when

controls. Although the increased lifespans of the males started on

treatment was started at 16 months (Table 1). Thus, 17aE2 joins rapa-

the 17aE2 diets at 16 or 20 months were not statistically different

mycin as an intervention effective later in life, although 17aE2 has

(log-rank test), males that started treatment at 16 months tended to

no benefit for females. 17aE2, like rapamycin, works just as well in

live longer, as indicated both by pooled data (Table 1, Figure 1) and

males even though started in middle age (16 months) and almost as

site-specific data (Table 2). Providing a strong test of this impression

well when started as late as 20 months. Acarbose is a bit different:

would require higher numbers of animals.

started in middle age, it still works, but only about ½ as well as it does

A feature of the ITP design is that husbandry conditions and deri-

when it starts in young mice (Harrison et al., 2019).

vation of the mice are standardized across sites and time; thus, results

The dramatic sexual dimorphism in response to 17aE2 treat-

collected in different ITP studies of the same treatments are highly

ment may help elucidate aspects of the mechanism by which

6 of 10
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sex hormones regulate lifespan. In UM-HET3 mice, diet restric-

effects of short-term 18% diet restriction (DR) and dietary 17aE2

tion (DR) increases male and female lifespans to a similar degree

in 20-month-old male C57BL/6 mice. The 17aE2 had no effect on

(Flurkey et al., 2010). This is not the case for 17aE2. Both male and

protein-to-DNA synthesis rates compared with controls in any tis-

female mice given 14.4 ppm 17aE2 diets starting at 10 months of

sue, while 18% DR produced the large changes in protein-to-DNA

age were 14%–18% lighter than controls at 12, 18, and 24 months

synthesis rates expected with lifelong 40% DR. Using RNA-seq,

yet lifespans only increased in males (Strong et al., 2016, Figure 1,

Tyshkovskiy et al. (2019) found feminizing effects with most of

Figure S1), implying that the male-specific effects are not medi-

the anti-aging candidate drugs they tested, increasing RNAs char-

ated by DR.

acteristic of females and decreasing RNAs characteristic of males.

Rapamycin, like 17aE2, increases lifespan when treatment is initi-

Interestingly, the exception was 17aE2. It might be informative to

ated at 20 months of age; however, unlike 17aE2, rapamycin benefits

feed 17aE2 to young or middle-aged mice and see how quickly the

both male and female mice (Harrison et al., 2009, 2014; Miller et al.,

RNA profile is modified to resemble that seen in mice given 17aE2

2011, 2014). Thus, the male-specific lifespan benefit of 17aE2 con-

for most of their lives.

trasts with other treatments that produce comparable benefits in

None of the other four drugs tested in the 2015 cohort, that is,

both sexes, making this model valuable for investigation of sexually

NR, CC, GGA, and MIF098, led to lifespan improvement in either

dimorphic, and potentially novel, mechanisms of aging.

sex. As reviewed in the introduction, in many species, total NAD lev-

Garratt et al. (2017, 2018) evaluated effects of 17aE2 feeding

els decline with age, increasing NAD levels benefits many physiolog-

on metabolic parameters in mature adult UM-HET3 mice of both

ical systems in mice and men, and a small increase in mouse lifespan

sexes. In mice started on 17aE2 at 4 months of age, and euthanized

was reported. Our finding that NR has no effect on lifespan in the

at 12 months of age, only intact (i.e., non-castrated) males showed

genetically variable mice that best model the human population is

increased insulin sensitivity and improved glucose tolerance, en-

thus a surprise. In fact, the two points of most interest in this paper

hanced hepatic mTORC2 signaling, increased Akt activity, and phos-

are that 17aE2 is effective when given later in life, and that NR has

phorylation of FOXO1a. Females and castrated males did not show

no effect on lifespan.

these changes, while ovariectomized females showed some of the

Each drug was detectable in food pellets, and metabolites of NR

benefits. Using mice treated at the same ages, Garratt et al. (2018)

and CC were detected in plasma of treated mice. While it is possible

found changes in liver amino acids, and urea cycling, in untargeted

that one or more of these drugs might have led to health benefits if

metabolomic analyses; these changes also were specific to intact

used at a different dose, or in another stock of mice, or if started or

males. If testicular hormones play an important role in lifespan ex-

stopped at a different age, the most plausible interpretation is that

tension when 17aE2 is given at 10–20 months of age, perhaps the

none of the drugs slows aging or prevents disease in a genetically

reduction in benefits observed between 16 and 20 months is partly

heterogeneous mouse population.

caused by a decline in androgen with age in male mice (Coquelin &

Lifespan studies of the ITP demonstrate that, when following

Desjardins, 1982). Only males (Garratt et al., 2018) had elevated lev-

precise standards, mouse lifespan can be reproducibly extended

els of two conjugated estriols when given 17aE2. This suggests that

by drugs in the diet (Harrison et al., 2009, 2014, 2019; Miller et al.,

males, but not females, metabolize 17aE2 into one or more estriol

2011, 2014; Miller, Harrison, et al., 2020; Strong et al., 2008, 2016).

derivatives and that the sex-specific beneficial effects may be due

Positive results are important, as showing here that 17aE2 is benefi-

to an estriol derivative rather than to 17aE2 per se. The ITP is test-

cial when started later in life. But negative results are also important,

ing this hypothesis by comparing lifespans in male and female mice

as showing here that NR failed to increase lifespan.

given diets containing estriol.
Strong et al. (2016) noted that 17aE2 at the standard 14.4 ppm
dose reduced body weights in females and altered uterine weights
in ovariectomized mice. Thus, 17aE2 is partially active in females,
so the absence of an effect on female lifespan is not because bioavailability is entirely absent. These observations support the idea

4
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E X PE R I M E NTA L PRO C E D U R E S

4.1 | Mouse production, maintenance, and
estimation of lifespan

that testicular hormones play an important role in lifespan extension
by 17aE2. Interestingly, the wide range of cancers that cause most

UM-HET3 mice were produced at each of the three test sites as pre-

deaths in UM-HET3 mice (Harrison et al., 2014; Lipman et al., 2004;

viously described (Harrison et al., 2009; Miller et al., 2011; Strong

Miller & Chrisp, 2002) most likely are postponed by 17aE2 to in-

et al., 2008), where environmental conditions are presented in de-

crease lifespan in males.

tail. The dams of the test mice were CByB6F1/J, TJL stock #100009

Stout et al. (2017) reported that 14.4 ppm 17aE2 alleviates

(dams, BALB/cByJ; sires, C57BL/6 J). The sires of the test mice were

age-
related metabolic and inflammatory dysfunction in 18-or

C3D2F1/J, TJL stock #100004 (dams, C3H/HeJ; sires, DBA/2 J). In

20-month-old male C57BL/6 mice treated for 10 or 15 weeks.

each site, breeding mice were fed LabDiet® 5008 mouse chow (PMI

Treated males showed reduced energy intake but not expenditure,

Nutritional International, Bentwood, MO). As soon as mice were

and reduced inflammation, fat, glucose, insulin, and mTOR complex

weaned, they were fed LabDiet® 5LG6 distributed to the test sites

1, while increasing AMPKα. Miller, Pharaoh, et al. (2020) compared

from the same batch. Males were initially housed 3 per cage, while
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females were housed 4 per cage; numbers per cage declined as mice

TJL’s definitive endpoint criterion is the non-responsiveness of a

died. Figure 4 shows that lifespans for both female and male controls

mouse to being touched, and which is usually accompanied by one

were similar at all 3 sites.

or more of the following: slow respiration, feeling cold to the touch,

Details of the methods used for health monitoring were pro-

a hunched-up appearance with matted fur, signs of sudden weight

vided previously (Harrison et al., 2009; Miller et al., 2011; Strong

loss, failure to eat and drink, prominent appearing ribs and spine,

et al., 2008). In brief, each of the three colonies was evaluated four

and sunken hips. The age at which a moribund mouse was eutha-

to twelve times each year for infectious agents. All such surveillance

nized was taken as the best available estimate of its natural lifespan.

tests were negative for pathogens at all three sites throughout the

Mice found dead were also noted at each daily inspection, giving

entire study period.

the lifespan.

4.2 | Removal of mice from the
longevity population

4.4 | Control and experimental diets
TestDiet®, Inc., a division of Purina Mills (Richmond, IN), prepared

Mice were removed from the study because of fighting or accidental

batches of radiation-
sterilized LabDiet® 5LG6 food which were

death (e.g., during chip implantation) or chip failure, or because they

ground to powder, and to which each test substance was added, as

were used for another experimental purpose. For log-rank survival

well as control diets from the same large batch treated the same

analyses, all such mice were “censored,” that is, treated as alive at

way except that no drugs were added when diets were ground and

the date of their removal from the protocol and lost to follow-up

mixed. These were prepared at intervals of approximately 4 months,

thereafter. These mice were not included in calculations of median

and TestDiet® shipped food from the same batch to each of the

longevity. For the mice in Table 1, % males removed: control, 9%;

three sites. For the interventions in this paper, except E2, the doses

17aE2-16, 3%; 17aE2-20, 10%; NR, 7%; CC, 12%; GGA, 13%; and

used were suggested by the experts who proposed the compound

MIF098, 6%. Most of these males were removed because of fight-

and were tested in pilot studies to be sure that the mice were not

ing. Fewer females were removed: control, 0.3%; NR, 1.5%; CC, 3%;

harmed over 8 weeks.

GGA, 0; and MIF098, 0.
Thus, mice removed from the longevity population were included

1. 17-α-estradiol (17aE2) was purchased from Steraloids Inc.

in log-rank test calculations. The question as to whether removal is ran-

(Newport, RI, USA) and mixed at a dose of 14.4 milligrams

dom does not apply, since no mice were removed for other purposes.

per kilogram diet (14.4 ppm). Male mice were fed the 17aE2

The statistical approach used is the usual Kaplan–Meier calculation,

diet continuously starting at either 16 or 20 months of age.

based on the log-rank test, in which mice that do not die a natural death

2. Nicotinamide riboside (NR) was generously provided by

(typically because of removal for humane reasons) are treated as known

ChromaDex, 1751 S Fordham Street, Ste:350, Longmont, CO

to be alive at the date of removal, with unknown date of death.

80503, as the chloride salt, and mixed at a dose of 1,000 mg NR
Chloride per kilogram diet (1,000 ppm). Mice were fed the NR

4.3 | Estimation of age at death (lifespan)

diet continuously starting at 8 months of age. Upon assay, the
amounts of NR plus nicotinamide totaled 878 ppm. For assay, control diet or plasma was spiked with known concentrations of NR

At UM and UT, mice were examined daily for signs of ill health from

and nicotinamide and compared with unknowns in the LC/MS/MS

the time they were set up in the experiment. At TJL, mice over

using mitoquinone D-15 as the internal standard. Assaying four

500 days of age were examined daily and twice a day once they

different batches of diet pellets, amounts of nicotinamide +NR in

were marked as ill. Mice were euthanized for humane reasons if so

ppm were as follows: 196 + 393 = 589 (67% of the expected level);

severely moribund that they were considered, by an experienced

371 + 414 = 785 (89% of expected); 101 + 551 = 652 (74% of ex-

technician, unlikely to survive for more than an additional 48 hours.

pected); and 241 + 453 = 695 (79% of expected).

F I G U R E 4 Effects of site on control
lifespans in this cohort. Panel A shows
females, and Panel B shows males. p
values are for median lifespans; controls
did not differ significantly among the sites
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3. Candesartan cilexetil (CC) and candesartan were purchased from

HARRISON et al.

The raw data used here are available at the Mouse Phenome

TOCRIS Bioscience (Bristol, United Kingdom); CC was mixed at a

Database

dose of 30 mg per kilogram diet (30 ppm). Mice were fed the CC

Laboratory, Bar Harbor, ME. This is supported by the Mouse

https://phenome.jax.org/projec ts/ITP1,

The

Jackson

diet continuously starting at 8 months of age. CC and candesartan

Phenome Project and is a public data repository that provides the

were quantified mixing calibrator samples and unknowns with 10

authoritative source for the raw and summary data from the ITP,

µL of 100 µg/mL withaferin A and 1 ml of mobile phase B, and

along with visualizations for exploration of lifespan and related phe-

assayed in the LC/MS/MS. The ratios of CC and candesartan peak

notype data.

areas to withaferin A peak areas for each unknown sample were
compared against the ratios obtained by the calibration samples

AC K N OW L E D G M E N T S

to quantify CC and candesartan. Nine separate batches of diet

This work was funded in part by NIA grants AG022308 (D.E.H.),

pellets were tested, with an average of 84% of the expected level

AG022303 (R.A.M.), and AG022307 and AG013319 (R.S.), with im-

(range: 58–122%).

portant facilities supported by CA034196 (TJL). Some of the stud-

4. Geranylgeranylacetone (GGA) was purchased from Sigma-Aldrich

ies at UM were supported by the Glenn Foundation for Medical

Chemical Company (St. Louis, MO) and mixed at a dose of 600 mg

Research. RS is supported by a Senior Research Career Scientist

per kilogram diet (600 ppm). Mice were fed the GGA diet con-

Award from the Department of Veterans Affairs Office of Research

tinuously starting at 9 months of age. GGA was quantified using

and Development. We wish to thank Pam J. Krason, Vicki Ingalls,

mixtures of known calibrators and unknown samples in the

Nelson Durgin, Natalie Perry, Lori Roberts, Roxann Alonzo, Ilkim

HPLC/UV. The peak area ratios for each unknown sample were

Erturk, Jacob Sheets, and Vivian Diaz for reliable technical assis-

compared against calibrator peak area ratios to quantify GGA. A

tance; Jesse Sanchez, Meredith Murrell, and Greg Friesenhahn for

similar method was described by Ding et al. (2007). Nine separate

excellent technical support in Analytical Pharmacology; and Joanne

batches of diet pellets were tested with an average of 73% of ex-

M. Currer for editorial assistance.

pected amounts of GGA (range: 16%–123%).
5. MIF098 was obtained from Cheminpharma (Woodbridge, CT) and
mixed at a dose of 240 mg per kilogram diet (240 ppm). Mice were

C O N FL I C T O F I N T E R E S T
None.

fed the MIF098 diet continuously starting at 8 months of age.
It was measured using spiked controls and injecting well-mixed

AU T H O R C O N T R I B U T I O N S

standard amounts of calibrator and unknown in the HPLC/UV.

DEH, RS, and R AM are the principal investigators at the three

Ratios of MIF 098 peak areas were compared to clonazepam peak

collaborating institutions and are responsible for project de-

area standards. In 9 different batches of diet pellets, the % of ex-

sign, supervision of technical personnel, interpretation of

pected amounts of MIF098 averaged 94% and ranged from 74%

results, and preparation of manuscript drafts. MAJ and MLC

to 112%.

supervised the Pharmacology Core and helped with the manuscript; JFN and KF advised on experimental design and inter-

The 2015 cohort of UM-HET3 mice was also used to test the

pretation and helped with the manuscript. NK and AB did NR

effects of canagliflozin, an inhibitor of SGLT2 (Miller, Harrison, et al.,

experiments. Laboratory manager PR supervised laboratory

2020).

procedures and data collection at The Jackson Laboratory site,
and organized diet preparations for all three sites. MB and TMS

4.5 | Statistical methods

analyzed data and organized the database. FM served as the
project officer for the National Institute on Aging and contributed to program development, experimental design, and analy-

Significance tests about survival effects are based upon the two-

sis. EF supervised laboratory personnel and data collection at

tailed log-rank test at p < 0.05, stratified by test site, with censored

the UTHSCSA site. ALS proposed NR; GC proposed CC; KK

mice included up until their date of removal from the longevity pop-

proposed GGA; RB and RM proposed MIF-0 98; and LL pre-

ulation. Data from male and female mice are considered separately.

pared it.

In statistical tests described in the text, P values are two-t ailed and
reported without adjustment for multiple comparisons. Statistical

DATA AVA I L A B I L I T Y S TAT E M E N T

claims related to maximum lifespan are based on Wang et al. (2004),

Mouse Phenome Database https://phenome.jax.org/projec ts/ITP1,

using the Fisher exact test to compare the proportions of surviving

The Jackson Laboratory, Bar Harbor, ME.

mice, in control and test groups, at the age corresponding to the 90th
percentile for survival in the joint distribution of the control and test

ORCID

groups. For the pooled data sets, surviving mice were enumerated

David E. Harrison

at the 90th percentile age for each site separately, and these counts
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were combined for the overall Fisher exact test.
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